Tiangang Li, PhD

Biography

Diabetes and non-alcoholic fatty liver disease (NAFLD) are closely associated with hepatic fat and cholesterol accumulation, hepatocyte organelle dysfunction, low grade inflammation, and dyslipidemia. Patients with diabetes and NAFLD have significantly higher risk of cardiovascular disease, which remains the leading cause of death worldwide. Bile acids are synthesized from cholesterol only in the liver. Hepatic bile acid synthesis is the only major cholesterol catabolic elimination mechanism in the body, and bile acids act as physiological detergents to facilitate dietary lipid and fat-soluble vitamin absorption in the small intestine. Furthermore, bile acids are signaling molecules that critically regulate metabolic homeostasis and inflammatory response by activating nuclear receptors and intracellular signaling pathways. Different therapeutic approaches targeting the bile acid signaling pathways have shown great promise for treating metabolic and chronic liver diseases including cholestasis, dyslipidemia, diabetes, and fatty liver disease. A major focus of the lab is to investigate how modulating the enterohepatic bile acid signaling impacts the complex metabolic network via distinct mechanism of actions. Through these studies, we hope to better understand the pathophysiological function of bile acids and to help establish the molecular basis for developing effective bile acid-based therapies. Current ongoing projects include:

1. Bile acid signaling crosstalk with Transcriptional Factor EB (TFEB), a nutrient sensing master regulator of lysosomal biogenesis and autophagy, in the regulation of cholesterol and bile acid metabolism.

2. Bile acid regulation of amino acid metabolism in control of hepatic glucose metabolism, insulin sensitivity and obesity development.

3. Pharmacological modulation of hepatic insulin resistance in fatty liver disease.

4. Bile acid signaling in aging-associated hepatic oxidative stress and drug-induced liver injury.

We address these questions by employing experimental mouse models through viral vector-mediated liver-specific gene delivery, tissue-specific genetic knockout, and pharmacological treatment approaches and a combination of physiological, molecular cell biology techniques and unbiased transcriptomics and metabolomics approaches.

Email

Tiangang-Li@ouhsc.edu

Additional Websites

• Publications
• OUHSC Profile

Research Interests:

• Cholesterol and bile acid metabolism
• Fatty liver disease
• Cholestasis
• Insulin Resistance
• Lipid metabolism